Hematologic Malignancies: Translating Discoveries to Novel Therapies

May 6-9, 2017
Westin Boston Waterfront
Boston, Massachusetts

Saturday, May 6

Plenary Session 1: Initiating and Stem Cells in Hematologic Malignancies
4:00 p.m.-5:30 p.m.

Hijacking of emergency myelopoiesis pathways in myeloid leukemia
Emmanuelle Passegué, Columbia University, New York, New York

Mechanisms of formation and progression of pre-leukemic stem cells
Ulrich G. Steidl, Albert Einstein College of Medicine, Bronx, NY

Additional speaker to be announced

Break
5:30 p.m.-5:45 p.m.

Welcome Remarks / Opening Keynote Lecture
5:45 p.m.-7:00 p.m.

Engineered T cells: Opportunities and challenges
Carl H. June, University of Pennsylvania, Philadelphia, Pennsylvania

Opening Reception
7:00 p.m.-9:00 p.m.

Sunday, May 7

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.

Plenary Session 2: The Cellular and Molecular Basis of Drug Resistance and Response to Therapy
8:00 a.m.-10:00 a.m.

Genetics and mechanisms of chemotherapy resistance in relapse acute lymphoblastic leukemia
Adolfo Ferrando, Columbia University, New York, New York

Tumor heterogeneity and clonal evolution in CLL in relationship to therapy
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

Intratumor heterogeneity and its role in therapeutic escape in multiple myeloma
Rodger E. Tiedemann, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 short talks from proffered abstracts

Break
10:00 a.m.-10:30 a.m.

Plenary Session 3: Chemical Biology
10:30 a.m.-12:30 p.m.
Title to be announced
Nathanael S. Gray, Dana-Farber Cancer Institute, Boston, Massachusetts

Therapeutic targeting of epigenetic regulators in acute leukemia
Jolanta E. Grembecka, University of Michigan, Ann Arbor, Michigan

Targeting the CRL4\textsuperscript{CRBN} E3 ligases for treatment of hematological cancers
Rajesh Chopra, The Institute for Cancer Research, London, United Kingdom

Targeted therapies as molecular probes for comprehensive pre-clinical evaluation
Mark Dawson, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

Poster Session / Lunch
12:30 p.m.-2:30 p.m.

Plenary Session 4: Aberrant RNA Metabolism
2:30 p.m.-4:30 p.m.
Spliceosome gene mutations in MDS: Biology and potential therapeutic strategies
Matthew J. Walter, Washington University School of Medicine, St. Louis, Missouri

Title to be announced
Catriona H. M. Jamieson, UCSD Moores Cancer Center, La Jolla, California

RNA regulators and the control of self-renewal
Michael G. Kharas, Memorial Sloan Kettering Cancer Center, New York, New York

2 short talks from proffered abstracts

Evening on Own
4:30 p.m.-

Monday, May 8

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.

Plenary Session 5: Genomics
8:00 a.m.-10:15 a.m.

Genetic predisposition to hematopoietic malignancies
Lucy A. Godley, University of Chicago, Chicago, Illinois
Title to be announced
Elli Papaemmanuil, Memorial Sloan Kettering Cancer Center, New York, New York

Title to be announced
Charles G. Mullighan, St. Jude Children's Research Hospital, Memphis, Tennessee

**Development of targeted therapies for lymphoma guided by genomics**
Louis M. Staudt, National Cancer Institute, Bethesda, Maryland

1 short talk from proffered abstracts

**Break**
10:15 a.m.-10:45 a.m.

**Plenary Session 6: Cell Death Pathways**
10:45 a.m.-12:45 p.m.

**Directing blood cancer therapy with mitochondrial BH3 profiling**
Anthony G. Letai, Dana-Farber Cancer Institute, Boston, Massachusetts

**CDK6: At the interface of Rb and p53**
Veronika Sexl, VetmedUni, Institute of Pharmacology and Toxicology, Vienna, Austria

**Immunomodulatory therapy of multiple myeloma with IAP antagonists**
Marta Chesi, Mayo Clinic Arizona, Scottsdale, Arizona

2 short talks from proffered abstracts

**Lunch / Networking Roundtables**
1:00 p.m.-3:00 p.m.

**Plenary Session 7: Immunotherapy**
3:00 p.m.-5:00 p.m.

**CAR T cell editing for cancer immunotherapy**
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

**Engineering effective and safe T cell therapy**
Stanley R. Riddell, Fred Hutchinson Cancer Research Center, Seattle, Washington

**Targetable genetic bases of immune evasion in lymphoma**
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, Massachusetts

**Epigenetic regulation of cancer immune surveillance processes**
Ricky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, Australia

**Panel Discussion: Immunotherapy**
5:00 p.m.-5:45 p.m.
Tuesday, May 9

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.

Plenary Session 8: Epigenetics
8:00 a.m.-10:15 a.m.

Role of mutations in epigenetic modifiers in leukemic transformation
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, New York

The role of the NSD2 histone methyltransferase in lymphoid malignancies
Jonathan D. Licht, University of Florida Health Cancer Center, Gainesville, Florida

Epigenetic program in aging and MDS
Maria E. Figueroa, University of Miami, Miami, Florida

Additional speaker to be announced

1 short talk from proffered abstracts

Break
10:15 a.m.-10:30 a.m.

Plenary Session 9: Tumor Microenvironment and Tumor-Host Interaction
10:30 a.m.-12:30 p.m.

Metabolic vulnerabilities in AML
David T. Scadden, Massachusetts General Hospital, Boston, Massachusetts

Image-based tracking of cancer heterogeneity and therapy resistance
Tannishtha Reya, University of California San Diego, La Jolla, California

Targeting immune receptor mutations in lymphoma
Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, New York

2 short talks from proffered abstracts

Departure
12:30 p.m.